Literature DB >> 18326965

Identifying early cardiovascular disease to target candidates for treatment.

Daniel A Duprez1, Jay N Cohn.   

Abstract

Most attempts to identify individuals at risk for cardiovascular morbid events have involved screening for risk factors. These traditional risk factors do not identify the underlying atherosclerotic disease nor assess the severity of disease in individual patients. The goal for identifying a marker or markers for early cardiovascular disease that could serve as a surrogate for disease progression and ultimate morbid events is to improve the precision for early detection and treatment. The authors utilize a variety of techniques, which consist of 7 vascular tests (large and small artery elasticity, resting blood pressure and exercise blood pressure response, optic fundus photography, carotid intimal-media thickness, and microalbuminuria) and 3 cardiac tests (electrocardiography, [N-terminal pro-] B-type natriuretic peptide, and left ventricular ultrasonography). Each test is individually scored, and the total disease score is the sum of all the test scores. A study is ongoing to compare the new disease score vs the classical Framingham risk estimate in the prediction of cardiovascular events.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18326965      PMCID: PMC8109885          DOI: 10.1111/j.1751-7176.2008.07429.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  40 in total

1.  Screening for early detection of cardiovascular disease in asymptomatic individuals.

Authors:  Jay N Cohn; Lynn Hoke; Wayne Whitwam; Paul A Sommers; Anne L Taylor; Daniel Duprez; Renee Roessler; Natalia Florea
Journal:  Am Heart J       Date:  2003-10       Impact factor: 4.749

2.  Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population.

Authors:  Hans L Hillege; Vaclav Fidler; Gilles F H Diercks; Wiek H van Gilst; Dick de Zeeuw; Dirk J van Veldhuisen; Rijk O B Gans; Wilbert M T Janssen; Diederick E Grobbee; Paul E de Jong
Journal:  Circulation       Date:  2002-10-01       Impact factor: 29.690

Review 3.  Surrogate markers for cardiovascular disease: structural markers.

Authors:  G B John Mancini; Björn Dahlöf; Javier Díez
Journal:  Circulation       Date:  2004-06-29       Impact factor: 29.690

Review 4.  Surrogate markers for cardiovascular disease: functional markers.

Authors:  Jay N Cohn; Arshed A Quyyumi; Norman K Hollenberg; Kenneth A Jamerson
Journal:  Circulation       Date:  2004-06-29       Impact factor: 29.690

Review 5.  Monitoring vascular health beyond blood pressure.

Authors:  Daniel A Duprez; Jay N Cohn
Journal:  Curr Hypertens Rep       Date:  2006-08       Impact factor: 5.369

Review 6.  34th Bethesda Conference: Task force #3--What is the spectrum of current and emerging techniques for the noninvasive measurement of atherosclerosis?

Authors:  Rita F Redberg; Robert A Vogel; Michael H Criqui; David M Herrington; Joao A C Lima; Mary J Roman
Journal:  J Am Coll Cardiol       Date:  2003-06-04       Impact factor: 24.094

7.  Prediction of coronary heart disease using risk factor categories.

Authors:  P W Wilson; R B D'Agostino; D Levy; A M Belanger; H Silbershatz; W B Kannel
Journal:  Circulation       Date:  1998-05-12       Impact factor: 29.690

8.  Computerized measurement of retinal blood vessel calibre: description, validation and use to determine the influence of ageing and hypertension.

Authors:  Antonio Pose-Reino; Francisco Gomez-Ulla; Bashir Hayik; Marta Rodriguez-Fernández; María J Carreira-Nouche; Antonio Mosquera-González; Manuel González-Penedo; Francisco Gude
Journal:  J Hypertens       Date:  2005-04       Impact factor: 4.844

9.  Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study.

Authors:  Olli T Raitakari; Markus Juonala; Mika Kähönen; Leena Taittonen; Tomi Laitinen; Noora Mäki-Torkko; Mikko J Järvisalo; Matti Uhari; Eero Jokinen; Tapani Rönnemaa; Hans K Akerblom; Jorma S A Viikari
Journal:  JAMA       Date:  2003-11-05       Impact factor: 56.272

Review 10.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I.

Authors:  Morteza Naghavi; Peter Libby; Erling Falk; S Ward Casscells; Silvio Litovsky; John Rumberger; Juan Jose Badimon; Christodoulos Stefanadis; Pedro Moreno; Gerard Pasterkamp; Zahi Fayad; Peter H Stone; Sergio Waxman; Paolo Raggi; Mohammad Madjid; Alireza Zarrabi; Allen Burke; Chun Yuan; Peter J Fitzgerald; David S Siscovick; Chris L de Korte; Masanori Aikawa; K E Juhani Airaksinen; Gerd Assmann; Christoph R Becker; James H Chesebro; Andrew Farb; Zorina S Galis; Chris Jackson; Ik-Kyung Jang; Wolfgang Koenig; Robert A Lodder; Keith March; Jasenka Demirovic; Mohamad Navab; Silvia G Priori; Mark D Rekhter; Raymond Bahr; Scott M Grundy; Roxana Mehran; Antonio Colombo; Eric Boerwinkle; Christie Ballantyne; William Insull; Robert S Schwartz; Robert Vogel; Patrick W Serruys; Goran K Hansson; David P Faxon; Sanjay Kaul; Helmut Drexler; Philip Greenland; James E Muller; Renu Virmani; Paul M Ridker; Douglas P Zipes; Prediman K Shah; James T Willerson
Journal:  Circulation       Date:  2003-10-07       Impact factor: 29.690

View more
  5 in total

1.  Effect of nebivolol or atenolol vs. placebo on cardiovascular health in subjects with borderline blood pressure: the EVIDENCE study.

Authors:  Daniel A Duprez; Natalia Florea; Sue Duval; Catherine Koukol; Jay N Cohn
Journal:  J Hum Hypertens       Date:  2017-11-28       Impact factor: 3.012

2.  The problem with cardiovascular disease prevention guidelines.

Authors:  Jay N Cohn; Daniel A Duprez
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-12

3.  Untreated HIV infection and large and small artery elasticity.

Authors:  Jason V Baker; Daniel Duprez; Joshua Rapkin; Katherine Huppler Hullsiek; Harrison Quick; Richard Grimm; James D Neaton; Keith Henry
Journal:  J Acquir Immune Defic Syndr       Date:  2009-09-01       Impact factor: 3.731

4.  Are more tests needed?

Authors:  Norman M Kaplan
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-03       Impact factor: 3.738

5.  The clinical and nonclinical values of nonexercise estimation of cardiovascular endurance in young asymptomatic individuals.

Authors:  Mahmoud A Alomari; Dana M Shqair; Omar F Khabour; Khaldoon Alawneh; Mahmoud I Nazzal; Esraa F Keewan
Journal:  ScientificWorldJournal       Date:  2012-04-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.